Podcasts

Dr Jacob highlights the progress of SunRISe-1: a phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk non–muscle-invasive bladder cancer unresponsive to BCG who are ineligible for or...

Dr Melani discusses results and safety outcomes of the ViPOR trial with venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide to treat R/R and untreated MCL, presented at the 2021 Annual ASH Meeting.

Thomas Slavin, MD, reviews ways to improve polygenic risk scores (PRS) in breast cancer by reducing ancestral bias, presented at the 2021 San Antonio Breast Cancer Symposium.

John Mascarenhas, MD, provides insight on the treatment of myelofibrosis patients with the TGF-β 1/3 Inhibitor AVID200 (MPN-RC 118), presented at the 2021 Annual ASH Meeting.

Mark Wildgust, PhD, highlights results from the Phase 3 CASSIOPEIA study of daratumumab as maintenance therapy in first-line MM treatment after stem cell transplant, presented at the 2021 Annual ASH Meeting.

Mark Wildgust, PhD, reviews real-world evidence examining potential healthcare disparities- highlighting patient characteristics, treatment patterns and outcomes for Black and White patients with multiple myeloma who initiated treatment with...

Charu Aggarwal, MD, discusses incorporating plasma-based next-generation sequencing to improve guideline-concordant molecular testing in patients with newly diagnosed metastatic nonsquamous NSCLC.

Stephen Williams, MD, MS, FACS, discusses the SunRISe-2 trial evaluating the efficacy of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy in patients with muscle-invasive urothelial carcinoma.

Dr Linden shares encouraging results from the AMEERA-1 trial of SAR439859 for ER+/HER2- metastatic breast cancer, presented at the virtual SABCS Annual Meeting.

Tapan M. Kadia, MD, highlights a phase 2 trial on venetoclax plus intensive chemotherapy in patients with newly diagnosed AML or MDS.